News & Events

RIBOXX PHARMACEUTICALS and TOLLYS S.A.S announce an exclusive license agreement for treatment of Toll-like 3 positive cancers

February 04, 2016 —  Radebeul (Germany) & Lyon (France) — RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and TOLLYS SAS, a biotech company developing new therapeutic strategies in cancer, today announced that they have signed a license agreement that grants TOLLYS exclusive global development and commercialization rights to a new drug development program, which RIBOXX will refer to as APOXXIM®. Under the terms of the license agreement, TOLLYS will assume sole responsibility for global development and commercialization of APOXXIM® product candidate. Riboxx will be responsible for manufacturing and supply of APOXXIM® to TOLLYS.

APOXXIM® is a Toll-like Receptor 3 (TLR3)-ligand that eliminates cancer cells by activating the TLR3 pathway. APOXXIM® displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma.  APOXXIM® is manufactured with the unique patented cGMP TENPORA®-Process of Riboxx.

Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are very thrilled to start this collaboration with TOLLYS, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM®, RIBOXXOL® and QUADROXXIM®, mainly focusing on cancer immunotherapy."

Jacques-François Martin, President of TOLLYS declared: "TOLLYS is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-Ligands such as APOXXIM® to treat cancer has been extensively studied in the past decades by scientists at TOLLYS, with a particular focus on TLR3-positive cancers".

About RIBOXX PHARMACEUTICALS
RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in cancer immunotherapy. RIBOXX IP portfolio includes 17 PCT patent families so far, with 8 PCT patents granted in EU and/or Japan.

About TOLLYS SAS
TOLLYS SAS is a biotech company developing drugs targeting TLR3-positive cancer cells. TOLLYS SAS has a strong expertise in the design and development of anti-cancer strategies through activation of TLR3-pathway.

For further information, please contact
Dr. Jacques ROHAYEM
CEO & CSO
RIBOXX PHARMACEUTICALS
www.riboxx-pharma.com
Tel. 0049 351 8336010
business.development@riboxx.com

Jacques-François MARTIN
President
TOLLYS SAS
Tel. 0033 4 78426389
Email.     jfmartin@parteurop.fr

Read more …

Riboxx sammelt Geld in der Crowd (Transkript / 31.07.2014)

31.07.2014 - Als erstes deutsches Biotech-Unternehmen sammelt die Riboxx GmbH in der Crowd Geld für die Entwicklung eines Krebsimpfstoffs. Mit Erfolg: Das Mindestvolumen von 100.000 Euro wurde binnen weniger Stunden erreicht.

Read more …

Crowdinvesting soll der Biotech-Firma Riboxx eine Therapiestudie finanzieren (Biosaxony/30.07.2014)

Die Biotech-Firma Riboxx aus Radebeul hat mit dem Medikamentenkandidaten „Riboxxim“ ein heißes Eisen gegen Krebs im Feuer. Mit dem Geld privater Investoren, die über die Dresdner Crowdfunding-Plattform Seedmatch gewonnen werden sollen, möchte Riboxx nun in einer klinischen Phase I-Studie die Sicherheit und Wirksamkeit des Wirkstoffes testen.

Read more …

Erstes deutsches Pharma-Unternehmen im Crowdfunding

Das Dresdner Pharma-Startup Riboxx entwickelt Medikamente, die darauf zielen, Krebsrückfälle durch das „Einschalten des Immunsystems“ zu verhindern. Um möglichst weitgehend unabhängig von Pharma-Konzernen forschen zu können, möchte das Start-up die ersten Tests an Patientien mit Hilfe der Crowd finanzieren.

Read more …

Cookies faciliate the providing of our online services. By using our online services, you agree to our use of cookies.